Company intelligence / Profile preview
Captain T Cell
Schoenefeld/Berlin, Brandenburg, Germanycaptaintcell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Captain T Cell’s lead autologous candidate (CTC 127) has shown best-in-class efficacy in vivo (preclinical models); proprietary allogeneic TCR platform has achieved key proof-of-concept data for off-the-shelf cell therapy in solid tumors. No clinical data yet; first-in-human trial planned for 2027
- Therapeutic areas
- Oncology
- Modalities
- T cell receptor engineered T cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (founding partner/support)Ascenion (technology transfer partner)Bayer Co.Lab Berlin (life sciences incubator/mentoring and infrastructure partnership)
Beyond the preview
Go deeper on Captain T Cell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Captain T Cell.